- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Patent holdings for IPC class A61P 19/10
Total number of patents in this class: 1887
10-year publication summary
63
|
38
|
91
|
139
|
121
|
105
|
111
|
109
|
92
|
3
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Takeda Pharmaceutical Company Limited | 2945 |
40 |
Daiichi Sankyo Company, Limited | 1863 |
28 |
Novartis AG | 11297 |
22 |
Osaka University | 3288 |
17 |
The Regents of the University of California | 19479 |
16 |
Radius Health, Inc. | 93 |
14 |
Bristol-myers Squibb Company | 4886 |
12 |
Merck Patent GmbH | 5849 |
12 |
Chugai Seiyaku Kabushiki Kaisha | 1315 |
12 |
Sanofi | 3863 |
12 |
Boehringer Ingelheim International GmbH | 4762 |
11 |
Amgen Inc. | 3894 |
11 |
Kyowa Hakko Kirin Co., Ltd. | 284 |
11 |
Bayer Schering Pharma AG | 431 |
10 |
Wisconsin Alumni Research Foundation | 3819 |
10 |
Asahi Kasei Pharma Corporation | 139 |
10 |
sanofi-aventis | 396 |
10 |
Astellas Pharma Inc. | 1122 |
9 |
Mochida Pharmaceutical Co., Ltd. | 345 |
9 |
University of Pittsburgh - Of the Commonwealth System of Higher Education | 3034 |
9 |
Other owners | 1602 |